65,437 trials
Cognitive Impairment Associated With Schizophrenia
Primary: Mean Inter-trial Coherence (ITC) Magnitude of 40 Hz-derived Auditory Steady-state Response (ASSR) in HC and SZ Participants at Baseline — 0.432; 0.364 ITC (40Hz*msec)
Cervical Cancer
Primary: Primary Event (Acute Hematologic or GI Toxicity) — 55; 46 Participants
Obstructive Sleep Apnea
Primary: Apnea/Hypopnea Index — 2.9; 3.2 events/h
Melanoma
Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants
Intracranial Aneurysms · Seizure
Primary: Incidence of Seizure — 2; 1; 0; 0 Participants
Metastatic Prostate Carcinoma · Prostate Carcinoma Metastatic in the Bone · Stage IV Prostate Cancer
Primary: Mean Standardized Uptake Value (SUVmean) by Lesion Type — 1.91; 2.36; 2.63; 3.05 SUV by body weight (kg)
Dental Implants
Primary: Change in Bone Ridge Width at Crest — 0.84; 0.01 millimeters
Vascular Stent-Graft Stenosis
Primary: Number of Subjects With Loss of Primary Patency of Target Lesion — 81 Participants
Overweight · Obesity · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Body Weight (Percentage [%]) — -12.5; -3.6 Percentage change — p=<0.0001
Alzheimer Disease
Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76
HIV/AIDS · Hypertension
Primary: Controlled Hypertension — 3; 315; 37; 1 Participants
Adolescent Behavior · Hiv
Primary: Proportion of Missed Visits — 406; 433 Scheduled visits — p=0.631
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Pain and/or Tenderness — 5; 4; 1; 6 Participants
Pancreatic Cancer · Advanced Cancer
Primary: Disease Control Rate (DCR) — 0; 1; 1; 1 Participants
Presbyopia
Primary: Visual Analog Scale — 22 Participants